Dr. Gerhard Emrich

For patients with metastatic melanoma who fail to durably respond to PD-1 inhibitors, fecal microbiota transplantation (FMT) combined with reintroduction of anti-PD-1 therapy seems promising.

With the KEYNOTE-189 study, combined immunochemotherapy became the new first-line standard for metastastatic nonsquamous non-small-cell lung cancer. A recent update of the trial now reveals that patients with brain or liver metastasis benefit as well as patients without metastases.

Current studies evaluate the potency of immunotherapy combinations to improve response rates and prevent resistance to monotherapy treatment. Now, current data of an ongoing phase I/II trial evaluating combined TIM-3/PD-1 inhibition were presented.

For human papillomavirus associated tumors, standard chemotherapy regimens show only limited efficacy. An ongoing phase I trial evaluating immunotherapy M7824 delivered encouraging data.

Elaine R. Mardis, PhD, is the new president-elect of the American Association of Cancer Research. In this video, she talks about her goals during her presidency and what the appointment means to her.

Mohammed Milhem presents preliminary data on the combination of the TLR9 agonist CMP-001 and pembrolizumab in patients with metastatic melanoma resistant to anti-PD-1.

In our SKE-session, Prof. Solange Peters, Lausanne, and Prof. Reinhard Dummer, Zurich, discussed recent findings concerning immunotherapy in lung cancer and melanoma.

Prof. Solange Peters presents the newest data on immunotherapy in NSCLC.